Journal article
Searching for candidate genes in familial BRCAX mutation carriers with prostate cancer
SM Hunter, SM Rowley, D Clouston, J Li, R Lupat, N Krishnananthan, G Risbridger, R Taylor, D Bolton, IG Campbell, H Thorne
Urologic oncology | Published : 2016
Abstract
Copyright © 2016 Elsevier Inc. All rights reserved. CONCLUSIONS: In all, 10 truncating or missense variants showed either complete or partial segregation with PC in the relevant families. CYP3A43 and PARP2 variants have been shown to occur in other familial PCs and our findings add to the contribution that these variants potentially have in the risk and development of PC in BRCAX cases. OBJECTIVE: A family history of prostate cancer (PC) is a well-recognized high-risk factor for the development of clinically significant PC. To date, traditional linkage and association studies have identified only a limited number of genes and specific gene variants that account for only a small proportion of..
View full abstractRelated Projects (1)
Grants
Funding Acknowledgements
We wish to thank Eveline Niedermayr, all the kConFab research nurses and staff, the heads and staff of the Family Cancer Clinics, and the many families who contribute to kConFab. kConFab is supported by a grant from the National Breast Cancer Foundation, Australia, and previously by the National Health and Medical Research Council (NHMRC), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia, and the Cancer Foundation of Western Australia. We acknowledge the support of Professor Mark Frydenberg, Lead Investigator, The Cancer of the Prostate Translational Research in Victoria (CAPTIV) collaboration and Professor Ian Davis, chair, CAPTIV key technologies program.